{"pmid":32320375,"title":"Logic in the time of coronavirus.","text":["Logic in the time of coronavirus.","Much has happened here since the local news media trumpeted the first Australian COVID-19 fatality, and stirred up a medieval fear of contagion. We now need to take a step back to examine the logic underlying the use of our limited COVID-19 countermeasures. Emerging infectious diseases by their nature, pose new challenges to the diagnostic-treatment-control nexus, and push our concepts of causality beyond the limits of the conventional Koch-Henle approach to aetiology. We need to use contemporary methods of assessing causality to ensure that clinical, laboratory and public health measures draw on a rational, evidence-based approach to argumentation. The purpose of any aetiological hypothesis is to derive actionable insights into this latest emerging infectious disease. This review is an introduction to a conversation with medical microbiologists, which will be supported by a moderated blog.","J Med Microbiol","Inglis, Timothy J J","32320375"],"abstract":["Much has happened here since the local news media trumpeted the first Australian COVID-19 fatality, and stirred up a medieval fear of contagion. We now need to take a step back to examine the logic underlying the use of our limited COVID-19 countermeasures. Emerging infectious diseases by their nature, pose new challenges to the diagnostic-treatment-control nexus, and push our concepts of causality beyond the limits of the conventional Koch-Henle approach to aetiology. We need to use contemporary methods of assessing causality to ensure that clinical, laboratory and public health measures draw on a rational, evidence-based approach to argumentation. The purpose of any aetiological hypothesis is to derive actionable insights into this latest emerging infectious disease. This review is an introduction to a conversation with medical microbiologists, which will be supported by a moderated blog."],"journal":"J Med Microbiol","authors":["Inglis, Timothy J J"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32320375","week":"202017|Apr 20 - Apr 26","doi":"10.1099/jmm.0.001191","keywords":["covid-19","sars-cov-2","coronavirus","countermeasures","principles of aetiology"],"source":"PubMed","topics":["General Info"],"weight":1,"locations":["Australian"],"countries":["Australia"],"countries_codes":["AUS|Australia"],"_version_":1664815087790063616,"score":8.518259,"similar":[{"pmid":32120913,"pmcid":"PMC7141128","title":"Epidemiological Identification of A Novel Pathogen in Real Time: Analysis of the Atypical Pneumonia Outbreak in Wuhan, China, 2019-2020.","text":["Epidemiological Identification of A Novel Pathogen in Real Time: Analysis of the Atypical Pneumonia Outbreak in Wuhan, China, 2019-2020.","Virological tests have now shown conclusively that a novel coronavirus is causing the 2019-2020 atypical pneumonia outbreak in Wuhan, China. We demonstrate that non-virological descriptive characteristics could have determined that the outbreak is caused by a novel pathogen in advance of virological testing. Characteristics of the ongoing outbreak were collected in real time from two medical social media sites. These were compared against characteristics of eleven pathogens that have previously caused cases of atypical pneumonia. The probability that the current outbreak is due to \"Disease X\" (i.e., previously unknown etiology) as opposed to one of the known pathogens was inferred, and this estimate was updated as the outbreak continued. The probability (expressed as a percentage) that Disease X is driving the outbreak was assessed as over 29% on 31 December 2019, one week before virus identification. After some specific pathogens were ruled out by laboratory tests on 5 January 2020, the inferred probability of Disease X was over 49%. We showed quantitatively that the emerging outbreak of atypical pneumonia cases is consistent with causation by a novel pathogen. The proposed approach, which uses only routinely observed non-virological data, can aid ongoing risk assessments in advance of virological test results becoming available.","J Clin Med","Jung, Sung-Mok","Kinoshita, Ryo","Thompson, Robin N","Linton, Natalie M","Yang, Yichi","Akhmetzhanov, Andrei R","Nishiura, Hiroshi","32120913"],"abstract":["Virological tests have now shown conclusively that a novel coronavirus is causing the 2019-2020 atypical pneumonia outbreak in Wuhan, China. We demonstrate that non-virological descriptive characteristics could have determined that the outbreak is caused by a novel pathogen in advance of virological testing. Characteristics of the ongoing outbreak were collected in real time from two medical social media sites. These were compared against characteristics of eleven pathogens that have previously caused cases of atypical pneumonia. The probability that the current outbreak is due to \"Disease X\" (i.e., previously unknown etiology) as opposed to one of the known pathogens was inferred, and this estimate was updated as the outbreak continued. The probability (expressed as a percentage) that Disease X is driving the outbreak was assessed as over 29% on 31 December 2019, one week before virus identification. After some specific pathogens were ruled out by laboratory tests on 5 January 2020, the inferred probability of Disease X was over 49%. We showed quantitatively that the emerging outbreak of atypical pneumonia cases is consistent with causation by a novel pathogen. The proposed approach, which uses only routinely observed non-virological data, can aid ongoing risk assessments in advance of virological test results becoming available."],"journal":"J Clin Med","authors":["Jung, Sung-Mok","Kinoshita, Ryo","Thompson, Robin N","Linton, Natalie M","Yang, Yichi","Akhmetzhanov, Andrei R","Nishiura, Hiroshi"],"date":"2020-03-04T11:00:00Z","year":2020,"_id":"32120913","week":"202010|Mar 02 - Mar 08","doi":"10.3390/jcm9030637","keywords":["bayes' theorem","causation","diagnosis","epidemic","prediction","statistical model"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"locations":["Wuhan","China","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664640875029856256,"score":93.27114},{"pmid":32139372,"pmcid":"PMC7081812","title":"What we know so far: COVID-19 current clinical knowledge and research.","text":["What we know so far: COVID-19 current clinical knowledge and research.","In December 2019, health authorities in Wuhan, China, identified a cluster of pneumonia cases of unknown aetiology linked to the city's South China Seafood Market. Subsequent investigations revealed a novel coronavirus, SARS-CoV-2, as the causative agent now at the heart of a major outbreak. The rising case numbers have been accompanied by unprecedented public health action, including the wholesale isolation of Wuhan. Alongside this has been a robust scientific response, including early publication of the pathogen genome, and rapid development of highly specific diagnostics. This article will review the new knowledge of SARS-CoV-2 COVID-19 acute respiratory disease, and summarise its clinical features.","Clin Med (Lond)","Lake, Mary A","32139372"],"abstract":["In December 2019, health authorities in Wuhan, China, identified a cluster of pneumonia cases of unknown aetiology linked to the city's South China Seafood Market. Subsequent investigations revealed a novel coronavirus, SARS-CoV-2, as the causative agent now at the heart of a major outbreak. The rising case numbers have been accompanied by unprecedented public health action, including the wholesale isolation of Wuhan. Alongside this has been a robust scientific response, including early publication of the pathogen genome, and rapid development of highly specific diagnostics. This article will review the new knowledge of SARS-CoV-2 COVID-19 acute respiratory disease, and summarise its clinical features."],"journal":"Clin Med (Lond)","authors":["Lake, Mary A"],"date":"2020-03-07T11:00:00Z","year":2020,"_id":"32139372","week":"202010|Mar 02 - Mar 08","doi":"10.7861/clinmed.2019-coron","keywords":["2019-ncov","sars-cov-2","wuhan","coronavirus","respiratory tract infection"],"source":"PubMed","topics":["Mechanism","Diagnosis","Transmission","Prevention"],"weight":1,"locations":["Wuhan","China","Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664640874937581571,"score":81.66653},{"pmid":32330312,"title":"Does pandemic justify the use of Hydroxychloroquine for treatment and prevention of COVID-19 in India?","text":["Does pandemic justify the use of Hydroxychloroquine for treatment and prevention of COVID-19 in India?","The Indian Council of Medical Research (ICMR), recommended the use of hydroxychloroquine (HCQ) as a prophylactic against COVID-19 among health care workers and asymptomatic contacts of laboratory confirmed cases of COVID. This is widely criticised as a hastily taken step with political inclination and minimal evidence backing. In the current scenario, where there is mass fear against COVID-19, this recommendation has made the people to believe that it will kill the viruses. This has important public health implications which are discussed below. Better communication should have been planned to ensure everyone does not go out and buy it. However, as a nation of 1.3 billion, we need to capitalize on this opportunity to generate data and valuable evidence on the use of HCQ to beat this pandemic. All health care workers taking this drug should volunteer themselves to be part of a trial/observational study and get registered online to generate useful data related to its safety and efficacy and guide future recommendations. The other risk group which includes asymptomatic contacts of laboratory confirmed COVID-19 patients are under surveillance by the state and local health authorities and could also be roped into this study to generate robust evidence. Of course, pandemic does not just justify the use of HCQ, but pandemic is the time to innovate, think out of box and generate evidence to prove the same so that we can lives. This article is protected by copyright. All rights reserved.","J Med Virol","Tripathy, Jaya Prasad","32330312"],"abstract":["The Indian Council of Medical Research (ICMR), recommended the use of hydroxychloroquine (HCQ) as a prophylactic against COVID-19 among health care workers and asymptomatic contacts of laboratory confirmed cases of COVID. This is widely criticised as a hastily taken step with political inclination and minimal evidence backing. In the current scenario, where there is mass fear against COVID-19, this recommendation has made the people to believe that it will kill the viruses. This has important public health implications which are discussed below. Better communication should have been planned to ensure everyone does not go out and buy it. However, as a nation of 1.3 billion, we need to capitalize on this opportunity to generate data and valuable evidence on the use of HCQ to beat this pandemic. All health care workers taking this drug should volunteer themselves to be part of a trial/observational study and get registered online to generate useful data related to its safety and efficacy and guide future recommendations. The other risk group which includes asymptomatic contacts of laboratory confirmed COVID-19 patients are under surveillance by the state and local health authorities and could also be roped into this study to generate robust evidence. Of course, pandemic does not just justify the use of HCQ, but pandemic is the time to innovate, think out of box and generate evidence to prove the same so that we can lives. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Tripathy, Jaya Prasad"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330312","week":"202017|Apr 20 - Apr 26","doi":"10.1002/jmv.25933","keywords":["covid-19","coronavirus","hydroxychloroquine","pandemic"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Hydroxychloroquine","India"],"countries":["India"],"countries_codes":["IND|India"],"_version_":1664996914933792769,"score":80.70466},{"pmid":32246783,"title":"Response to Commentary on \"The neuroinvasive potential of SARS-CoV-2 may play a role in the respiratory failure of COVID-19 patients\".","text":["Response to Commentary on \"The neuroinvasive potential of SARS-CoV-2 may play a role in the respiratory failure of COVID-19 patients\".","In a recent review, we have suggested a neuroinvasive potential of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its possible role in the causation of acute respiratory failure of coronavirus disease 2019 (COVID-19) patients (J Med Viol doi: 10.1002/jmv.25728), based upon the clinical and experimental data available on the past SARS-CoV-1 and the recent SARS-CoV-2 pandemic. In this article, we provide new evidence recently reported regarding the neurotropic potential of SARS-CoV-2 and respond to several comments on our previously published article. In addition, we also discuss the peculiar manifestations of respiratory failure in COVID-19 patients and the possible involvement of nervous system.","J Med Virol","Li, Yan-Chao","Bai, Wan-Zhu","Hashikawa, Tsutomu","32246783"],"abstract":["In a recent review, we have suggested a neuroinvasive potential of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its possible role in the causation of acute respiratory failure of coronavirus disease 2019 (COVID-19) patients (J Med Viol doi: 10.1002/jmv.25728), based upon the clinical and experimental data available on the past SARS-CoV-1 and the recent SARS-CoV-2 pandemic. In this article, we provide new evidence recently reported regarding the neurotropic potential of SARS-CoV-2 and respond to several comments on our previously published article. In addition, we also discuss the peculiar manifestations of respiratory failure in COVID-19 patients and the possible involvement of nervous system."],"journal":"J Med Virol","authors":["Li, Yan-Chao","Bai, Wan-Zhu","Hashikawa, Tsutomu"],"date":"2020-04-05T11:00:00Z","year":2020,"_id":"32246783","week":"202014|Mar 30 - Apr 05","doi":"10.1002/jmv.25824","keywords":["cell susceptibility","coronavirus","dissemination","nervous system"],"source":"PubMed","weight":0,"_version_":1664638040113414144,"score":80.303894},{"pmid":32278766,"title":"Fighting against COVID-19: Innovative strategies for clinical pharmacists.","text":["Fighting against COVID-19: Innovative strategies for clinical pharmacists.","BACKGROUND: Clinical pharmacists' routine task is carrying out pharmaceutical care to ensure patients' safe and reasonable medication use. However, under public health emergencies, such as the outbreak of COVID-19, the work strategies of clinical pharmacists need to be modified according to the rapid spread of the disease, where information and resources are usually lack to guide them. OBJECTIVE: To retrieve and investigate the prevention and control measures of clinical pharmacists during the outbreak of novel coronavirus, summarize the roles and responsibilities of clinical pharmacists, and to propose innovative strategies for developing pharmacy services under the epidemic. METHODS: The Chinese and English databases, self-media network, website of professional society or medical institution, and clinical trial center platforms were searched, and clinical pharmacists involved in the work against COVID-19 were surveyed and interviewed. Investigate the challenges and needs of frontline medical staffs for treating patients, and formulate strategies based on the actual medical environment. RESULTS: Clinical pharmacists play a vital role in leading the industry to formulate work instructions, provide frontline medical staff with drug information, and develop innovative pharmacy services to promote the rational use of medicines with collaborative teamwork and close communication according to the epidemic situation of COVID-19. Anti-epidemic work indeed has driven the development of remote pharmacy services. CONCLUSION: Facing public health emergencies, clinical pharmacists can give full play to their professional expertise, analyze the current situation rationally, formulate telehealth strategies swiftly, and work in a united and efficient manner to provide innovative pharmacy services to ensure medication safety and rational use of medicine.","Res Social Adm Pharm","Li, Huibo","Zheng, Siqian","Liu, Fang","Liu, Wei","Zhao, Rongsheng","32278766"],"abstract":["BACKGROUND: Clinical pharmacists' routine task is carrying out pharmaceutical care to ensure patients' safe and reasonable medication use. However, under public health emergencies, such as the outbreak of COVID-19, the work strategies of clinical pharmacists need to be modified according to the rapid spread of the disease, where information and resources are usually lack to guide them. OBJECTIVE: To retrieve and investigate the prevention and control measures of clinical pharmacists during the outbreak of novel coronavirus, summarize the roles and responsibilities of clinical pharmacists, and to propose innovative strategies for developing pharmacy services under the epidemic. METHODS: The Chinese and English databases, self-media network, website of professional society or medical institution, and clinical trial center platforms were searched, and clinical pharmacists involved in the work against COVID-19 were surveyed and interviewed. Investigate the challenges and needs of frontline medical staffs for treating patients, and formulate strategies based on the actual medical environment. RESULTS: Clinical pharmacists play a vital role in leading the industry to formulate work instructions, provide frontline medical staff with drug information, and develop innovative pharmacy services to promote the rational use of medicines with collaborative teamwork and close communication according to the epidemic situation of COVID-19. Anti-epidemic work indeed has driven the development of remote pharmacy services. CONCLUSION: Facing public health emergencies, clinical pharmacists can give full play to their professional expertise, analyze the current situation rationally, formulate telehealth strategies swiftly, and work in a united and efficient manner to provide innovative pharmacy services to ensure medication safety and rational use of medicine."],"journal":"Res Social Adm Pharm","authors":["Li, Huibo","Zheng, Siqian","Liu, Fang","Liu, Wei","Zhao, Rongsheng"],"date":"2020-04-13T11:00:00Z","year":2020,"_id":"32278766","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.sapharm.2020.04.003","keywords":["covid-19","hospital pharmacy","pharmacy service","rational use of medicine","telehealth"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664636873240215552,"score":80.132614}]}